Janux Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€376.66K - Cost of goods sold
€464.18K - Gross profit
-€87.52K - SG&A expenses
€39.62M - R&D expenses
€85.06M - EBITDA
-€123.43M - D&A
€876.88K - EBIT
-€124.31M - Interest expenses
€0.00 - EBT
-€90.64M - Tax expenses
€0.00 - Net income
-€90.64M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€8.58M - Changes in working capital
€13.05M - Operating cash flow
-€51.30M - Capex
€781.64K - Other investing cash flow
€0.00 - Net investing cash flow
-€250.73M - Total cash dividends paid
€0.00 - Issuance of common stock
€320.84M - Debt repayment
€0.00 - Other financing cash flow
€9.43M - Net financing cash flow
€334.45M - Foreign exchange effects
€0.00 - Net change in cash
€32.42M - Cash at end of period
€45.70M - Free cash flow
-€50.52M
Balance sheet
- Cash and cash equivalents
€45.00M - Cash and short-term investments
€854.58M - Total receivables
€4.88M - Inventory
€0.00 - Other current assets
€3.30M - Total current assets
€862.77M - Property, plant & equipment
€19.86M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€700.13K - Other non-current assets
€2.31M - Total non-current assets
€22.87M - Total assets
€885.64M - Accounts payable
€2.98M - Short-term debt
€1.61M - Other current liabilities
€13.75M - Total current liabilities
€18.34M - Long-term debt
€34.86M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€17.43M - Total liabilities
€35.78M - Common stock
€50.62K - Retained earnings
-€253.22M - Other equity
€3.21M - Total equity
€849.86M - Total liabilities and shareholders' equity
€885.64M
Company information
- Market capitalization
€1.17B - Employees
91 - Enterprise Value
€1.46B
Company ratios
- Gross margin
-
-23.2% Much better than peer group: -522.4% - EBITDA margin
-
-32,769.2% Much worse than peer group: -13,228.6% - EBIT margin
-
-33,002.1% Much worse than peer group: -18,984.2% - EBT margin
-
-24,064.0% Much better than peer group: -283,320.6% - Net margin
-
-24,064.0% Much worse than peer group: -12,433.7% - ROE
-
-10.7% Much better than peer group: -270.9% - ROA
-
-10.2% Much better than peer group: -290.2% - Asset turnover
-
0.0% Much worse than peer group: 126.3% - FCF margin
-
-13,827.8% Much better than peer group: -26,980.9% - FCF yield
-4.5% - Efficiency ratio
32,869.2% - Net sales per employee
-
€4.14K - Net income per employee
-
-€996.04K